XENE Q3 2025 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$77M

Operating Income

-$96M

Net Income

-$91M

EPS (Diluted)

$-1.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$72M

Free Cash Flow

-$72M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$608M

Total Liabilities

$48M

Stockholders' Equity

$560M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$77M	$0	—
Operating Income	-$96M	-$74M	-30.8%
Net Income	-$91M	-$63M	-44.8%